Confined or spread disease-Spread beyond the prostate gland - Page 4 of 10 Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Evaluating a radionuclide treatment for metastatic castration-resistant prostate cancer

Evaluating a radionuclide treatment for metastatic castration-resistant prostate cancer

Posted by on Mar 26, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of a radionuclide (RN), [¹??Lu]-PSMA-617, to treat metastatic castration-resistant prostate cancer (mCRPC) that has worsened after standard treatments. They found that this treatment was safe and effective for these patients. Some background Prostate cancer (PC) affects the...

Read More

Searching for patients with advanced prostate cancer to test a new drug combination

Posted by on Mar 16, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 3 trial will evaluate the safety and effectiveness of olaparib (Lynparza) and abiraterone (Zytiga) combination in prostate cancer. The main outcome will be the rate of survival without cancer growing or spreading. The details Prostate cancer (PC) is cancer that originates in the prostate gland. When cancer progresses to a...

Read More

Looking for men with prostate cancer to test chemotherapy in combination with radiotherapy

Looking for men with prostate cancer to test chemotherapy in combination with radiotherapy

Posted by on Feb 23, 2019 in Prostate cancer | 0 comments

In a nutshell This trial evaluates the effectiveness of using chemotherapy in combination with radium-223 (a type of internal radiotherapy). The main outcome to be measured is overall survival. This trial is taking place in the United States. The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...

Read More

Looking for men with prostate cancer, resistant to male hormone suppression, to be treated with medication and radiotherapy

Looking for men with prostate cancer, resistant to male hormone suppression, to be treated with medication and radiotherapy

Posted by on Jan 20, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluates the effectiveness of medication and focal radiation in the treatment of prostate cancer resistant male hormone suppression. The main outcome to be measured in this trial is the number of patients whose cancer does not grow or spread and who are alive at 18 months after treatment. This trial is taking place in Ann...

Read More

Evaluating stereotactic ablative body radiotherapy treatment option for low volume advanced prostate cancer

Evaluating stereotactic ablative body radiotherapy treatment option for low volume advanced prostate cancer

Posted by on Nov 10, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic ablative body radiotherapy (SABR) used as a treatment in low volume metastatic (spread) prostate cancer. This study found that SABR is effective and has few side-effects. Some background Stereotactic ablative body radiotherapy (SABR) is a treatment option...

Read More

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 6, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...

Read More

Outcomes of palliative resections of the prostate in patients with locally advanced prostate cancer

Outcomes of palliative resections of the prostate in patients with locally advanced prostate cancer

Posted by on Jul 24, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the usefulness of transurethral resection of the prostate (TURP). This study found that TURP is a surgical option to relieve bladder obstruction in patients with locally advanced prostate cancer. Some background Advanced prostate cancer may cause significant complications which affect...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More